The Alzheimer's Drug Discovery Foundation (ADDF) supports promising research projects from around the world to develop new drugs for Alzheimer's and related dementias, including vascular, Lewy body, and frontotemporal dementias.

Our goal is to accelerate the development of therapies through four core areas:

  1. Drug discovery
  2. Clinical trials
  3. Biomarkers
  4. Prevention

The ADDF is interested in novel therapeutic approaches, including small molecules, biologics, and gene therapies. Because the mechanisms underlying Alzheimer's disease and related dementias are varied and complex, we maintain a diverse portfolio of drug targets. We invite you to explore our portfolio to learn more about funded projects, and visit our Funding Opportunities page for current Requests for Proposals (RFP) and upcoming deadlines.

Our Current Portfolio by Drug Targets


• Calcium regulation
• Growth/neurotrophic factors
• Neuronal degeneration
• Neuronal regeneration and repair
• Oxidative stress

Misfolded Proteins

• Proteostasis
• Tau, TDP43, Synuclein


• Neuroinflammation
• Systemic inflammation

Genetics & Epigenetics

• Epigenetics


• Cognitive and functional outcomes
• CSF and peripheral biomarkers
• Neuroimaging and functional activity measure

Mitochondria & Metabolic Function

Synaptic Activity & Neurotransmitters



• Endocrinology
• Pharmacoeconomics


Please note: The ADDF no longer funds anti-amyloid approaches and has limited interest in funding cholinesterase inhibitor programs.


If you are considering applying for funding, log into or a create an account in the ADDF Grants Portal.